Aktieanalys

Biovica: A considerable boost in the clinical use of DiviTum tests - Redeye

Redeye Publicerad: 12 Sep 09:38

Biovica records IVD test sales in Q1 of SEK 0.62m, which is 50% above the previous quarter (Q4) and >100% above the earlier quarter (Q3), despite the late spring reorganisation of the US sales force. The RUO sales relating to pharma had a modest contribution. Still, in this segment, Biovica has already established a positive trend, as illustrated by the recent Master Service agreement win, bringing the total to 15 (with five different accounts) with an initial sales contribution of SEK 0.75m. Biovica recently also secured a directed new share issue of units, bringing SEK 16.4m without rebate to the recent share price.

Länk till analysen i sin helhet: https://www.redeye.se/research/1039557/biovica-a-considerable-boost-in-the-clinical-use-of-divitum-tests?utm_source=finwire&utm_medium=RSS

Nyheter om Biovica

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!